These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25556617)

  • 81. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
    Grignani G; Martín-Broto J; Schuler M; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A review of trabectedin (ET-743): a unique mechanism of action.
    D'Incalci M; Galmarini CM
    Mol Cancer Ther; 2010 Aug; 9(8):2157-63. PubMed ID: 20647340
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
    Tewari D; Saffari B; Cowan C; Wallick AC; Koontz MZ; Monk BJ
    Gynecol Oncol; 2006 Sep; 102(3):421-4. PubMed ID: 16797679
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience.
    Marchetti C; Musella A; Romito A; Vertechy L; Palaia I; Di Donato V; Boccia S; De Felice F; Monti M; Muzii L; Benedetti Panici P
    Oncology; 2017; 93(6):359-366. PubMed ID: 28946142
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
    van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
    BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Trabectedin: novel insights in the treatment of advanced sarcoma.
    Lopez JP; Gajdos C; Elias A
    Curr Oncol Rep; 2014 Jun; 16(6):387. PubMed ID: 24756367
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
    Shoji T; Takatori E; Kaido Y; Omi H; Yokoyama Y; Mizunuma H; Kaiho M; Otsuki T; Takano T; Yaegashi N; Nishiyama H; Fujimori K; Sugiyama T
    Cancer Chemother Pharmacol; 2014 May; 73(5):895-901. PubMed ID: 24585045
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?
    Cannistra SA
    J Clin Oncol; 2010 Jul; 28(19):3101-3. PubMed ID: 20516442
    [No Abstract]   [Full Text] [Related]  

  • 90. Trabectedin.
    Chuk MK; Balis FM; Fox E
    Oncologist; 2009 Aug; 14(8):794-9. PubMed ID: 19684073
    [No Abstract]   [Full Text] [Related]  

  • 91. Clinical benefit of trabectedin in uterine adenosarcoma.
    Schroeder BA; Rodler ET; Loggers ET; Pollack SM; Jones RL
    Med Oncol; 2013 Jun; 30(2):501. PubMed ID: 23456619
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
    Wuntakal R; Seshadri S; Montes A; Lane G
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma.
    Martinez-Trufero J; Alfaro J; Felipo F; Alvarez M; Madani J; Cebollero A
    Anticancer Drugs; 2010 Sep; 21(8):795-8. PubMed ID: 20622667
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Going further in the knowledge of Yondelis®; what's new in clinical trials?
    Blay JY
    Future Oncol; 2014 Jun; 10(8 Suppl):s7-s12. PubMed ID: 25048046
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.
    Mayer C; Brucker J; Schuetz F; Domschke C; Bechstein S; Heil J; Golatta M; Wallwiener M; Sohn C; Schneeweiss A; Rom J
    Arch Gynecol Obstet; 2016 Jul; 294(1):123-9. PubMed ID: 26498757
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Trabectedin in soft tissue sarcomas.
    Brodowicz T
    Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Recurrent epithelial ovarian cancer: an update on treatment.
    Foley OW; Rauh-Hain JA; del Carmen MG
    Oncology (Williston Park); 2013 Apr; 27(4):288-94, 298. PubMed ID: 23781692
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
    Koinis F; Polyzos A; Christopoulou A; Zafeiriou Z; Emmanouilidis C; Papadimitraki E; Kalykaki A; Kalbakis K; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):819-25. PubMed ID: 24531559
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin.
    Takano M; Ikeda Y; Kudoh K; Kita T; Sasaki N; Kikuchi Y
    J Obstet Gynaecol Res; 2013 Apr; 39(4):872-5. PubMed ID: 23167774
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas.
    Khoury R; Assi T; Ibrahim R; Ibrahim T; Verret B; Henon C; Bahleda R; Le Cesne A
    Curr Treat Options Oncol; 2024 Feb; 25(2):176-190. PubMed ID: 38324075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.